MENU

Can ReposiTrak (TRAK) Stock Reach $16?

a developer of proprietary software products

A.I.Advisor
published price charts
A.I.Advisor
Nov 10, 2026

Can ReposiTrak (TRAK) Stock Reach $16?

ReposiTrak, Inc. (TRAK), the Utah-based software-as-a-service provider behind the ReposiTrak Traceability Network and food-supply-chain compliance platform, has fallen sharply from its 52-week high and now trades near its recent lows. With the stock recently changing hands around $7.12, the question for investors is whether shares can climb back toward the $16 level that remains the lone price target on Wall Street. The answer is not a simple yes or no: the $16 objective reflects a single analyst's view, and the required move is very large.

Key Takeaways

  • The central target is $16.00, but it is a single analyst's price target — from Maxim Group's Tom Forte — not a multi-analyst consensus, because TRAK currently has effectively one active published target.
  • The latest verified price is about $7.12, meaning shares would need to rise roughly 125% to reach $16, a very large move.
  • The 52-week range is approximately $6.61 to $15.44, so $16 sits just above the prior 52-week high — a level the stock has touched before.
  • The strongest supporting factor is the U.S. Food and Drug Administration's food traceability rule (FSMA Section 204), which is driving demand for ReposiTrak's traceability network.
  • The biggest risks include a delayed FDA enforcement timeline, a fourth-quarter revenue decline, slowing growth, and very thin analyst coverage.
  • You can find more detail on the ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
  • To see how AI identifies changing trends across the market, explore Trending AI Robots.

Price Target Context and How $16 Was Established

Unlike widely covered mega-caps, TRAK has very limited sell-side coverage. Aggregators such as TipRanks and MarketBeat currently show roughly one active analyst rating on the stock. That single view comes from Maxim Group analyst Tom Forte, who reiterated a Buy rating and a $16.00 price target in May 2026 and again in September 2026. Because only one credible, current, attributable target exists, there is no meaningful multi-analyst consensus to average; accordingly, the $16 figure here is presented as a single-analyst objective drawn from public discussion, not an analyst consensus.

For context, historical coverage shows a wider range of past views. Forte previously maintained an $11 target while at D.A. Davidson, and a dated data source lists an older $24 average. These are not current and are noted only to illustrate how thin and shifting TRAK's coverage has been. The relevant point is that the lone current target — $16 — represents a return to just above the stock's prior 52-week high, making it an ambitious but not arbitrary reference point.

Current Market Position and Path Toward the Target

ReposiTrak recently closed near $7.12, down sharply from its 52-week high around $15.44 and not far above its 52-week low near $6.61. Reaching $16 would require roughly a 125% advance — a very large move by any measure, and one that would effectively require the stock to recover all of its recent decline and then set new highs.

Fundamentally, ReposiTrak is a small, profitable SaaS (software-as-a-service) business. Fiscal 2026 revenue grew 3% to about $23.3 million, with recurring revenue up 4%, while net income reached roughly $7.4 million and EPS (earnings per share) about $0.39. The balance sheet is notably clean, with around $27 million in cash and minimal debt, and the company pays a modest dividend. The path to $16 would most likely depend on a reacceleration in traceability revenue as the FDA's compliance deadlines approach, rather than on any single quarter.

What Could Support a Move Toward the Target

  • Regulatory demand. The FDA's Food Safety Modernization Act traceability rule requires enhanced recordkeeping for designated foods, positioning ReposiTrak's traceability network as a compliance solution for retailers and suppliers.
  • Recurring revenue. The company has been shifting its mix toward predictable subscription revenue, which supports valuation multiples.
  • Financial strength. Strong cash reserves, minimal debt, and consistent profitability give the company flexibility to invest and return capital.
  • New initiatives. Management has cited "touchless retailing" and its SPAR relationship as potential growth drivers expected to contribute more meaningfully in 2027 and beyond.

What Could Prevent the Target From Being Reached

  • Delayed enforcement. The FDA pushed its original January 2026 compliance date back to July 2028, and management linked a fourth-quarter revenue decline partly to an earlier rush of activity before the original deadline.
  • Slowing growth. Fiscal 2026 revenue rose only 3%, and fourth-quarter revenue declined year over year, weighing on sentiment.
  • Small-cap and coverage risk. A roughly $130 million market capitalization and minimal analyst coverage can amplify volatility and limit institutional support.
  • Valuation reset. Even after the decline, the stock trades at a meaningful P/E (price-to-earnings) multiple, and further multiple compression remains possible.

Technical Levels and Market Structure

The chart shows a stock that broke down from levels near $15 to the low single digits. The $16 target sits just above the 52-week high near $15.44, making that area a key overhead resistance zone and prior high. On the downside, the 52-week low near $6.61 is an important support level; a sustained close below it would undermine the bullish case. Between these extremes, round-number levels such as $10 and $12 are likely to act as psychological resistance zones on any recovery.

Time Horizon and What Investors Should Monitor

A $16 price target of this kind generally reflects a roughly 12-month research horizon, though with a single analyst the timeframe is inherently less precise. Key items to watch include the company's next earnings report, management's commentary on traceability demand and the FDA timeline, the ramp of touchless retailing, any analyst revisions, and progress on the company's stated goal of redeeming remaining preferred shares. Regulatory milestones around the 2028 FDA deadline will be the most important long-term catalyst.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a small-cap name like TRAK with limited analyst coverage, these signals can offer an additional, data-driven way to track shifting momentum and identify turning points as they emerge. Traders can use the tool to discover opportunities, monitor existing positions, and spot changing trends more efficiently.

Final Assessment

Can ReposiTrak (TRAK) stock reach $16? The target is real but rests on a single analyst's view rather than a broad consensus, and it demands a very large advance of roughly 125% from the current price near $7.12. The supporting case is anchored in regulatory tailwinds from food traceability requirements, a clean balance sheet, and recurring revenue, while the principal obstacles are a delayed FDA enforcement timeline, decelerating revenue growth, and thin coverage. For now, $16 represents a plausible return to the prior 52-week high rather than a near-term expectation, and investors should watch earnings, regulatory milestones, and any new analyst coverage for signals on whether that recovery thesis is gaining traction.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

TRAK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TRAK has been loosely correlated with VERX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if TRAK jumps, then VERX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRAK
1D Price
Change %
TRAK100%
-0.41%
VERX - TRAK
49%
Loosely correlated
+1.27%
OTEX - TRAK
48%
Loosely correlated
+0.20%
LSPD - TRAK
47%
Loosely correlated
+1.19%
SPSC - TRAK
47%
Loosely correlated
-1.16%
BL - TRAK
46%
Loosely correlated
+3.69%
More

Groups containing TRAK

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRAK
1D Price
Change %
TRAK100%
-0.41%
Packaged Software
industry (222 stocks)
27%
Poorly correlated
-1.06%
Technology Services
industry (396 stocks)
22%
Poorly correlated
-0.36%
Can ReposiTrak (TRAK) Stock Reach $16?